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Available online 13 January 2016Mitochondrial protein SURF1 is a speciﬁc assembly factor of cytochrome c oxidase (COX), but its function is poorly
understood. SURF1 gene mutations cause a severe COX deﬁciency manifesting as the Leigh syndrome in humans,
whereas in mice SURF1−/− knockout leads only to a mild COX defect. We used SURF1−/− mouse model for
detailed analysis of disturbed COX assembly and COX ability to incorporate into respiratory supercomplexes
(SCs) in different tissues and ﬁbroblasts. Furthermore, we compared ﬁbroblasts from SURF1−/− mouse and
SURF1 patients to reveal interspecies differences in kinetics of COX biogenesis using 2D electrophoresis,
immunodetection, arrest of mitochondrial proteosynthesis and pulse-chase metabolic labeling.
The crucial differences observed are an accumulation of abundant COX1 assembly intermediates, low content of
COX monomer and preferential recruitment of COX into I–III2–IVn SCs in SURF1 patient ﬁbroblasts, whereas
SURF1−/− mouse ﬁbroblasts were characterized by low content of COX1 assembly intermediates and milder
decrease in COX monomer, which appeared more stable. This pattern was even less pronounced in SURF1−/−
mouse liver and brain. Both the control and SURF1−/−mice revealed only negligible formation of the I–III2–IVn
SCs and marked tissue differences in the contents of COX dimer and III2–IV SCs, also less noticeable in liver and
brain than in heart and muscle. Our studies support the view that COX assembly is much more dependent on
SURF1 in humans than in mice. We also demonstrate markedly lower ability of mouse COX to form I–III2–IVn
supercomplexes, pointing to tissue-speciﬁc and species-speciﬁc differences in COX biogenesis.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Mammalian oxidative phosphorylation system (OXPHOS) consists
of ﬁvemultisubunit protein complexes and twomobile electron carriers
— ubiquinone and cytochrome c. Electron transporting complexes I–IV
(cI–cIV) form the respiratory chain (RC), where transfer of electrons
from reducing equivalents tomolecular oxygen leads to proton pumping
across the innermitochondrialmembrane (IMM), resulting inmitochon-
drial proton gradient formation. ATP synthase, complex V (cV), then uses
electrochemical potential of the proton gradient as a driving force for
ATP synthesis. Organization of RC complexes in the IMM appears to be
rather dynamic and individual RC complexes coexists with respiratory
supercomplexes (SCs) composed of cI, cIII and cIV [2]. As proposed byS, oxidative phosphorylation
tory chain; cI–cV, RC complexes
LS, Leigh syndrome; mtDNA,
. This is an open access article underthe “plasticity model” of the RC organization, SCs differ in various tissues
and cell types and their composition could be regulated according to
actual energetics demands and substrate availabilities [1].
Complex IV - cytochrome c oxidase (COX, cIV), the terminal enzyme
of the RC transfers electrons from reduced cytochrome c to oxygen
molecule embedded in its structure. In mammals, COX can be detected
as a monomer, dimer or as a part of several SCs. COX is formed by 14
different subunits. Three largest subunits COX1, COX2 and COX3 are
coded for by mitochondrial DNA (mtDNA) and represent the catalytic
core of the enzyme. Ten subunits (COX4, COX5a, COX5b, COX6c,
COX7b, COX7c, COX8, COX7a, COX6b, COX6a) encoded by nuclear
genes are involved in COX regulation, assembly, stability and dimeriza-
tion [20,26,58]. Recently, the NDUFA4, formerly described as complex I
subunit was recognized as the 14th nuclear encoded subunit of COX [6].
NDUFA4 is loosely attached to the assembled COX complex and appears
to be essential for enzyme biogenesis [48]. COX molecules also contain
severalmetal cofactors in two copper sites (CuA, CuB) and twohememoi-
eties (heme a and a3). Mammalian COX assembly pathway proceeds via
four/ﬁve step-by-step assembly intermediates S1–S2–S3–S4*–S4, where
S4 represents a fully assembled COX monomer [20]. COX biosynthesisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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depending on many ancillary/assembly proteins. They are essential
for different steps of COX biogenesis, from regulation of expression of
catalytic core subunits (LRPPRC, TACO1, hCOA3, COX14) [15,64,65,68],
through copper metabolism and insertion (COX17, SCO1, SCO2, COX11,
COX19, COA6, COX20) [10,22,31–34,43], heme a biosynthesis and inser-
tion (COX10, COX15, FDX2) [3,4,51], to membrane insertion and pro-
cessing of catalytic core subunits (OXA1l, COX18) [60]. A few other
COX assembly proteins have been identiﬁed; they participate in early
(SURF1, COA5) [24,60] or intermediate stages (PET100) [36] of COX
biogenesis, but their precise function is as of yet unknown.
SURF1 is a 30 kDa hydrophobic protein localized in the IMM,
encoded by a SURF1 nuclear gene, which is part of a highly conserved
housekeeping gene cluster, the surfeit locus [19,60,62,69]. Up to now,
SURF1 is supposed to be involved in a formation of S2 assembly interme-
diate, most likely in association of COX2 subunit with COX1–COX4–
COX5a subassembly [59,66]. However, its function might be more
redundant, because studies on yeast homolog Shy1 indicate, that Shy1/
SURF1 might play a role in heme a transfer/insertion into COX1 subunit
[7,57]. Tissue-dependent copper deﬁciency was found in patients
harboring SURF1 gene mutations, which points to a possible function
of SURF1 in maintaining of proper cellular copper homeostasis [58].
Moreover, a recently identiﬁed MITRAC12 protein [38] was found to in-
teract with SURF1 and COX1 in a mitochondrial translation regulation
assembly intermediate of COX1, which further extends possible roles
of the SURF1 in COX biogenesis.
Mutations in the human SURF1 gene result in a severe reduction of
fully assembled, active COX and accumulation of COX assembly inter-
mediates in patients' cells and tissues. SURF1mutationsmanifest usually
several months after birth as a fatal neurodegenerative mitochondrial
disorder, Leigh syndrome (LS) [52,70]. In recent studies 74 known
SURF1 gene mutations have been summarized and linked to LS and
atypical LS [35], but without genotype–phenotype correlation [5,12,46,
47,61,63]. To better understand SURF1 function, SURF1 knockout
mouse (SURF1−/− mouse) model was generated [18]. SURF1−/− mice
were smaller at birth, had mild reduction in motor skills at adult age
and COXactivitywas found to bemildly reduced in all tissues examined.
Interestingly, SURF1−/−mice showed prolonged lifespan compared to
wild-type littermates that was later assigned to enhanced insulin sensi-
tivity and increased mitochondrial biogenesis [17,49]. Animals were
also protected from neuronal damage induced by kainic acid accompa-
nied by reduced mitochondrial uptake of calcium ions [18]. In addition,
recent study revealed that loss of SURF1 initiates mitochondrial stress
response pathways, including mitochondrial biogenesis, the UPRMT and
Nrf2 activation [49].
In the present study, we used the SURF1−/− mouse model for
detailed analysis of disturbed COX assembly and COX ability to incorpo-
rate into respiratory SCs in different tissues and ﬁbroblasts. Further-
more, we examined SURF1−/− mouse ﬁbroblasts in comparison with
human ﬁbroblasts of patients with SURF1mutations to reveal interspe-
cies differences in kinetics of COX biogenesis pathway, from assembly
intermediates to SCs. We show an accumulation of abundant COX1 as-
sembly intermediates and preferential recruitment of COX into I–III2–
IVn SCs in SURF1 patient ﬁbroblasts, whereas SURF1−/− mouse ﬁbro-
blasts were characterized by much milder decrease in COX monomer,
which was also more stable. Interestingly, murine COX, both in the
wild type and in SURF1 knockout showed only limited preference to-
wards the formation of SCs.
2. Material and methods
2.1. Experimental material
For experiments different tissues were obtained from 3-month-old
SURF1−/− knockout B6D2F1 mice [18], generated by the insertion of
a loxP sequence in exon 7 of the mouse SURF1 gene, leading to anaberrant, prematurely truncated and highly unstable protein, and
from control wild type SURF1+/+ mice. Immortalized skin ﬁbroblasts
from control and SURF1−/−mouse [18] were cultured at 37 °C in 5% at-
mosphere of CO2 in aDMEMmedium supplemented by 10% fetal bovine
serum, 20mMHEPES (pH 7.5) and geneticin (50 μg/ml). The same con-
ditions were used for cultivation of human patients' skin ﬁbroblasts
lacking the SURF1 protein due to 845 del CT mutations of SURF1 gene
[44] and from controls, except that geneticin was replaced with penicil-
lin (10 μg/ml) and streptomycin (10 μg/ml). The project was approved
by the ethics committees of Institute of Physiology, CAS. Informed
consent was obtained from the parents of the patients according to
the Declaration of Helsinki of the World Medical Association.
2.2. Isolation of mitochondria
Muscle (hind leg) was minced in a K medium (150 mM KCl, 2 mM
EDTA, 50 mM Tris, pH 7.4) supplemented with protease inhibitor
cocktail (1:500, PIC from Sigma) and homogenized by ultra turrax IKA
(2× for 15 s, level 4) and glass-teﬂon homogenizer (600 rpm, 5 strokes).
5% (w/v) homogenate was centrifuged 10 min at 600 g and postnuclear
supernatant was centrifuged 10min at 10,000 g. Pelleted mitochondria
were washed once (10,000 g, 10 min) and resuspended in K medium.
Liver mitochondria were isolated from 10% homogenate prepared in
STEmedium(250mMsucrose, 10mMTris, 2mMEDTA, pH7.2) supple-
mented with PIC (1:500) using glass-teﬂon homogenizer (600 rpm, 7
strokes). Postnuclear (800 g, 10 min) supernatant ﬁltered through a
gauze was centrifuged for 15 min at 5200 g, pelleted mitochondria
were washed twice (13,000 g, 10 min) in STE with PIC and then resus-
pended in STE medium.
Heart mitochondria were isolated essentially as liver mitochon-
dria, except that postnuclear supernatant was centrifuged for 10 min
at 13,000 g.
Fibroblastmitochondriawere isolated according to Bentlage et al. [9]
with slightmodiﬁcations. Cells harvested using 0.05% trypsin and 0.02%
EDTAwere sedimented (600 g, 5 min) andwashed twice in phosphate-
buffered saline (PBS— 140mMNaCl, 5mMKCl, 8mMNa2HPO4, 1.5mM
KH2PO4, pH 7.2). Weighed cell pellet was suspended in ten times (w/v)
the amount of 10mMTris-bufferwith PIC (1:500) and homogenized by
teﬂon-glass homogenizer (8 strokes, 600 rpm). Immediately afterwards
1/5 volume of 1.5M sucrosewas added.Homogenatewas centrifuged at
600 g, 10min andmitochondria containing supernatantwas kept on ice.
Pellet was suspended in original volume of SEKTP (250 mM sucrose,
40mMKCl, 20mMTris, 2mMEGTA, pH 7.6, PIC 1:500), rehomogenized
(5 strokes, 800 rpm) and centrifuged at 600 g, 10min. The supernatants
were pooled and centrifuged 10,000 g, 10 min. Sedimented mitochon-
dria were washed with SEKTP (10,000 g, 10 min) and suspended in
SEKTP.
All isolations were performed at 4 °C and mitochondria were stored
at−80 °C. Protein concentration was measured according to [11].
2.3. Protein analysis by Blue Native PAGE (BNE) and BNE/SDS PAGE
Mitochondrial pellets were suspended in MB2 buffer (1.5 M ε-
aminocapronic acid, 150mMBis-tris, 0.5mMEDTA, pH 7.0), solubilized
with digitonin (8 g/g protein) for 15 min on ice and centrifuged for
20 min at 20,000 g, 4 °C. Samples for BNEwere prepared from superna-
tants by adding 1/20 volume of 5% SBG dye (Serva Blue G 250) in
750 mM ε-aminocapronic acid and 1/10 volume of 50% (v/v) glycerol.
Frozen cell pellets were resuspended in sucrose buffer (83 mM
sucrose, 6.6 mM imidazole/HCl, PIC 1:500, pH 7.0) [67] and sonicated
for 10 s to obtain 10% (w/v) suspension. Cell membranes were
sedimented for 30 min at 100,000 g, 4 °C, solubilized with digitonin
(4 g/g protein) in an imidazole buffer (2 mM ε-aminocapronic acid,
1mMEDTA, 50mMNaCl, 50mMimidazole, pH7.0) for 10min and cen-
trifuged at 30,000 g, 20 min at 4 °C [67]. For BNE analysis supernatants
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dye in 750mM ε-aminocapronic acid at a dye/digitonin ratio 1:8 (w/w).
Solubilized mitochondria were analyzed by Bis-tris BNE [56] on 5–
12% polyacrylamide gradient gels, cell membranes were analyzed by
imidazole BNE [67] on 5–16% polyacrylamide gradient gels using the
Mini-Protean apparatus (BioRad).
For two-dimensional separation by BNE/SDS PAGE, the stripes
of BNE gel were incubated in 1% SDS and 1% 2-mercaptoethanol for
1 h and then subjected to SDS PAGE on a 10% slab gel [55].
2.4. Western blot analysis
Proteins were transferred from the gels to PVDF membranes
(Immobilon-P, Millipore) using semidry electroblotting. The mem-
branes were blocked with 5% (w/v) non-fat dried milk in TBS (150 mM
NaCl, 10 mM Tris, pH 7.5) for 1 h and incubated 2 h or overnight at
4 °C with primary antibodies diluted in TBS with 0.1% Tween-20. Mono-
clonal primary antibodies to the following enzymes of OXPHOS were
used: SDHA (ab14715, Abcam), CORE1 (ab110252, Abcam), NDUFB6
(ab110244, Abcam), NDUFS3 (ab110246, Abcam), COX1 (ab14705,
Abcam). The detection of the signals was performed with the secondary
Alexa Fluor 680-labeled antibody (Life Technologies) using the Odyssey
ﬂuorescence scanner (LI-COR). Quantiﬁcation of detected signals from
BNE/SDS PAGEwas carried out in Aida Image Analyzer program, version
3.21.
2.5. Spectrophotometric assays
COX, cII (succinate:cytochrome c oxidoreductase (SCCR)) and citrate
synthase (CS) activities were measured as previously [44], cI
(NADH:cytochrome c oxidoreductase (NCCR)) activity was measured
as in [50].
2.6. Doxycycline treatment of the cells
Experiment was performed as described in [41]. Brieﬂy, ﬁbroblasts
(grown to 70% conﬂuence in DMEM medium) were treated with
15 μg/ml doxycycline (DOX) for 7 days and then washed 3 times with
PBS to withdraw DOX. Subsequently, the cells were collected at differ-
ent time points (0, 6, 16, 24, 48, 72 and 96 h) after DOX removal.
Weighed pellets of cellswere stored at−80 °C for analysis of solubilized
cell membranes by 2D BNE/SDS-PAGE. Two independent experiments
of DOX inhibition in human and mouse ﬁbroblasts were performed.
COX1 antibody signals from 2D Western blots were quantiﬁed using
Aida Image Analyzer v. 3.21 (Raytest). The relative distribution of signal
between individual COX forms (assembly intermediates, monomer,
dimer, supercomplexes) was determined from 2D blots. The total
COX1 signal for each given time point was calculated from 1D SDS
PAGE (see Fig. 4 E–H in the Data in Brief appendix) and normalized to
SDHA signal. COX1 signalwas then divided by the relative quantities ob-
tained in the ﬁrst step. The resulting datasets from each experimentTable 1
Changes in COX and CS activities in SURF1−/−mouse.
SURF1+/+ SURF1
COX CS COX/CS COX
Heart 3385.9 ± 120.8 2047.9 ± 136.7 1.7 2228.5
Muscle 2486.7 ± 39.5 451.5 ± 50.2 5.5 1110.7
Liver 1495.2 ± 63.4 253.7 ± 11.5⁎ 5.9 675.9
Brain 1527.2 ± 97.1 627.9 ± 28.2 2.4 744.5
Fibroblasts 459.3 ± 33.6 333.7 ± 15.3 1.4 248.3
COX and CS enzyme activities (nmol/min/mg protein) were measured spectrophotometrically
SURF1+/+ values was expressed in %. The values are mean ± S.E. (n = 5–7).
⁎ p b 0.05.
⁎⁎ p b 0.01.were resampled to [0, 100] interval and averaged values from two ex-
periments plotted as comparative 2D maps.
2.7. Metabolic pulse-chase labeling of mtDNA encoded proteins
Proteins encoded bymtDNAwere labeled using 35S-Protein Labeling
Mix (Met+ Cys; Perkin Elmer NEG072) by procedure described in [37].
Brieﬂy, cells were incubated for 16 h with chloramphenicol (40 μg/ml),
washed twice in PBS, and after 15 min incubation in DMEM medium
without methionine and cysteine (DMEM-Met-Cys) and 15min incuba-
tion in DMEM-Met-Cys with cycloheximide (CHX; 0.1 mg/ml), 35S-
Protein LabelingMix (350 μCi/150mmdish)was added. Cells were incu-
bated for 2 h, then 250 μMcoldMet and Cys was added and after 15min
cells were washedwith PBS+ 250 μMcoldMet and Cys and ﬁnally with
PBS. Cells were grown in standard DMEM medium supplemented with
5% (v/v) fetal bovine serum and harvested at different times (0.5 h, 6 h,
16 h, 24 h). Pellets of labeled cells weremixedwith the samew/w of un-
labeled cells, cell membranes were isolated, solubilized with digitonin
and analyzed by 2D BNE/SDS PAGE. Gels were stained in a Coomassie R
250 dye, dried and radioactivity was detected using Pharos FX™ Plus
Molecular Imager (Bio-Rad). COX1 radioactive signals from 2D gels
(Fig. 4 A, B, C, D) were quantiﬁed using Aida Image Analyzer v. 3.21
and relative quantities of individual COX forms (assembly intermediates,
monomer, supercomplexes) were used to divide the respective COX1
signal for given chase-time from 1D SDS PAGE, normalized to overall
radioactive signal in each time point. The resulting datasets from each
experiment were resampled to [0, 100] interval and plotted as compara-
tive 2D maps.
3. Results
3.1. Decreased COX activities in SURF1−/−mouse tissues and ﬁbroblasts
Analysis of RC activities in isolated mitochondria from SURF1−/−
mouse tissues and in ﬁbroblasts whole cell lysates showed that COX
activities related to activity of citrate synthase (CS) were decreased to
37–62% of control (heart 55%, liver 37%, brain 50%, muscle 48%, ﬁbro-
blasts 62%) (Table 1), as previously described in [18]. Activities of
other RC enzymes were not signiﬁcantly changed in SURF1−/−mouse
tissues/ﬁbroblasts (not shown). The activity of CS was increased
(22.7%) in SURF1−/− liver mitochondria but not in other tissues. This
may suggest some compensatory upregulation of mitochondrial
biogenesis, as observed previously in heart and skeletal muscle [49],
or in SURF1 patient cells [28]. In general, the COX defect in SURF1−/−
mouse tissues and ﬁbroblasts is less pronounced than in SURF1 patients'
ﬁbroblasts and tissues, where COX activity was decreased to 10–30% of
control values [44,59]. These results are in agreement with differences
in phenotype severity between SURF1−/− mice and SURF1 patients:
while patients suffer from fatal Leigh syndrome, SURF1−/−mice show
increased lifespan without considerable mitochondrial dysfunction
[18,49].−/− SURF1−/−/SURF1+/+
CS COX/CS COX COX/CS
± 190.7 2433.7 ± 218.2 0.9 65.8⁎⁎ 55.4⁎⁎
± 121.3 420.5 ± 27.8 2.6 44.7⁎⁎ 47.9⁎⁎
± 23.0 311.3 ± 14.2 2.2 45.2⁎⁎ 36.8⁎⁎
± 17.7 609.9 ± 24.1 1.2 48.7⁎⁎ 50.2⁎⁎
± 49.3 280.3 ± 28.4 0.9 54.1⁎⁎ 62.3⁎
in SURF1+/+ and SURF1−/−mouse tissues and ﬁbroblasts, ratio between SURF1−/− and
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COX assembly intermediates in SURF1−/−mouse tissues and ﬁbroblasts
We performed 2D BNE/SDS PAGE analysis in combination with
Western blot to detect and quantify various COX forms from assembly
intermediates to supercomplexes in examined SURF1+/+ and
SURF1−/− mouse tissues and ﬁbroblasts (Figs. 1, 2; Fig. 3 in the Data
in Brief appendix). Generally, decreased COX activities in various
SURF1−/− mouse tissues and ﬁbroblasts corresponded to decreased
total COX content on Western blots. The amount of fully assembled
forms of COX (monomer, dimer and COX-containing SCs) was down-
regulated in SURF1−/− mouse. In heart, liver and brain (Fig. 1 A, C, D;
Fig. 3 in the Data in Brief appendix) it was in good agreementwithmea-
sured COX activity (heart 53%, liver 39%, brain 64%), whereas in muscle
it was somewhat higher (82%) and in ﬁbroblasts lower (30%) (Fig. 1 B,
E), than expected from activity measurements, possibly due to semi-
quantitative character of WB immunodetection (antibody reactivity in
different tissues, large differences in amounts of different COX forms).
Relative distribution of individual COX forms varied considerably
between the studied control mouse tissues. Monomer represented the
dominant form in all tissues, with relative amount ranging from 50%
in heart to asmuch as 85–95% of total COX in brain and liver. Signiﬁcant
content of COX dimers (18–27%) and III2–IV SC (13–15%) was detectedFig. 1. Two-dimensional electrophoretic analysis of different COX forms present in SURF1−/−
supercomplexes were solubilized using 8 g digitonin/g protein of isolated mitochondria, sepa
by Western blots using speciﬁc antibodies to COX1 (cIV), CORE1 (cIII), NDUFB6 (cI) and ND
SURF1+/+ and SURF1−/−mice as well as ﬁbroblasts (F) of human control and SURF1 patient w
III2–IV SC (III2–IV), I–III2 SC (I–III2), I–III2–IVn SCs (I–III2–IVn), complex III dimer (cIII2), complexin heart andmuscle (Fig. 1 A, B; Fig. 2 A, B; Fig. 3 in the Data in Brief ap-
pendix), whereas in liver and brain we found only negligible amount of
these COX forms (Fig. 1 C, D; Fig. 2 C, D; Fig. 3 in the Data in Brief appen-
dix). Weak signals of COX were also detected above 1 MDa. These SCs
were larger than I–III2 SC (detected by strong cI and cIII signals) and
therefore presumably represent the I–III2–IVn SCs.
In SURF1−/− mouse tissues, the amount of assembled COX forms
was lower compared to SURF1+/+, but the COX monomer was still the
dominant form. COX dimer still represented 10–20% of total COX in
heart and muscle but it almost disappeared in liver and brain (Fig. 1
A–D; Fig. 2 A–D; Fig. 3 in the Data in Brief appendix). III2–IV SC was pre-
served in small amount in all tissues, and weak COX signals of higher I–
III2–IVn SCs were detected only in heart and muscle. In contrast to con-
trols, we detected increased content of COX1 assembly intermediates
(AI) in muscle and heart, representing approximately 10% of total COX
signal. In liver and brain, the accumulation of AI was negligible (Fig. 1
A–D; Fig. 2 A–D).
In SURF1+/+ mouse ﬁbroblasts, the COX monomer represented
more than 90% of total COX signal, the remainder being comprised of
small contribution of COX dimer, III2–IV and I–III2–IVn SCs (Fig. 1 E;
Fig. 3 in the Data in Brief appendix). In SURF1−/− mouse ﬁbroblasts,
the COX defect was more accentuated than in other mouse tissues —
we detected reduced signal of COX monomer, negligible content of I–mouse tissues and ﬁbroblasts and SURF1 patient ﬁbroblasts. Respiratory complexes and
rated by BNE in the ﬁrst dimension and SDS PAGE in the second dimension and detected
UFS3 (cI). For analysis, heart (A), muscle (B), liver (C), brain (D) and ﬁbroblast (E) of
ere used. COX1 assembly intermediates (COX1 AI), COX monomer (M), COX dimer (D),
I (cI).
Fig. 2. Distribution proﬁles of the COX1 signal in different COX forms resolved by BNE/SDS PAGE analysis. COX1 signals from two-dimensional electrophoretic analysis in Fig. 1 were
expressed as quantitative distribution proﬁles. SURF1+/+ and SURF1−/− mice heart (A), muscle (B), liver (C), brain (D) and ﬁbroblasts (E) and human control and SURF1 patient
ﬁbroblasts (F). Individual COX forms are indicated: COX1 assembly intermediates (COX1 AI), COX monomer (M), COX dimer (D), III2–IV SC (III2–IV), I–III2–IVn SCs (I–III2–IVn).
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which represented 30% of total COX signal (Fig. 1 E; Fig. 3 in the Data
in Brief appendix).
Other RC complexes (cI and cIII) were not affected by the COX defect
in SURF1−/−mouse tissues and ﬁbroblasts. As expected, the content of
COX-containing III2–IV SC was reduced (Fig. 1 A–E; Figs. 1, 2 in the
Data in Brief appendix).
3.3. SURF1 patient ﬁbroblasts preserve large I–III2–IVn supercomplexes
Given the marked differences in COX activities between SURF1
patient and SURF1−/− mouse ﬁbroblasts and respective controls, we
also performed 2D BNE/SDS PAGE analysis on human control and
SURF1 patient ﬁbroblasts to obtain interspecies comparison of the COX
assembly defect consequences. In human control ﬁbroblasts, COX was
mainly found as a monomer and I–III2–IVn SCs (Fig. 1 F). There was
also higher amount of COX dimer and III2–IV SC in comparison to
SURF1+/+mouse ﬁbroblasts (Fig. 1 E, F; Fig. 3 in the Data in Brief appen-
dix). In SURF1patientﬁbroblasts, two dominant COX formswere detect-
ed: the majority of fully assembled COX was detected in the I–III2–IVn
SCs and as the large amount of COX1 assembly intermediates. In con-
trast the signal of COX monomer represented less than 10% of total
COX, a pattern signiﬁcantly different to SURF1−/− mouse ﬁbroblasts
(Fig. 1 E, F; Fig. 3 in the Data in Brief appendix). Taken together, we
show that the COX defect due to lack of SURF1 caused by SURF1 gene
mutations/knockout exerts both tissue and species speciﬁcity.
3.4. COX supercomplexes assembly kinetics
Our present experiments indicate signiﬁcant differences in COX as-
sociation into III2–IV and I–III2–IVn SCs between human and mouse,
which can be observed both in control and SURF1-deﬁcient ﬁbroblasts.
To explore the dynamics of COX incorporation into supercomplexes, we
transiently treated cells with doxycycline (DOX), a reversible inhibitor
of mitochondrial translation, to deplete the cells of mtDNA encodedOXPHOS subunits [41]. Human and mouse control and SURF1-
deﬁcient ﬁbroblasts were cultured for 7 days in the presence of DOX
and, after DOX removal, cells were collected at different time points
(t0, t6, t16, t24, t48, t72, t96 h) to follow the assembly of newly synthe-
sized mitochondrial-encoded subunits into RC complexes and subse-
quently into associated supercomplexes.
First we checked the amount of remaining COX in cell homogenates
after DOX treatment. Using SDS PAGE and Western blot analysis (Fig. 4
in the Data in Brief appendix), we clearly showed lower levels of COX1
subunit in comparison with controls (DOX untreated cells) in all cell
lines studied. COX1 antibody signals normalized to signals of SDHA
were decreased to 30% and 34% in control and SURF1 patient ﬁbroblasts,
and to 20% and 23% in SURF1+/+ and SURF1−/−mouse ﬁbroblasts, re-
spectively. DOX treatment caused also slight decrease of cIII and cV
levels, yet the greatest decrease was, unsurprisingly, observed in the
content of cI, with its 7 mitochondrially encoded subunits.
Isolated membranes from ﬁbroblasts were subsequently solubilized
with digitonin (4 g/g protein) and analyzed by 2D BNE/SDS PAGE in
combination with Western blot. In both human ﬁbroblast lines, anti-
body detection of COX1 subunit signals revealed decrease in all COX
forms at time point t0 (Fig. 3 A, B, E, F). Apparently, human cells pre-
served the reported stoichiometric distribution of COX (COX1) among
COX assembly intermediates (AI), COX monomer, dimer and COX SCs
(III2–IV, I–III2–VIn) throughout the doxycycline treatment. The balance
between COX AI and monomer was also maintained during the time
course after DOX withdrawal. Speciﬁcally, in human control cells
(Fig. 3 A, E), the longer the cells were cultured after DOX removal, the
more COX monomer and SCs were synthesized and at time point
t96 h COX1 signal reached the original steady state (DOX untreated
cells). At all time points, the monomer was still the prevalent COX
form. In SURF1 patients' ﬁbroblasts (Fig. 3 B, F) at t0 (after DOX remov-
al), COX monomer was the main COX assembled form as its level
decreased less than the content of COX associated into I–III2–IVn SCs.
At t0 and all successive time points, signals of COX1 assembly interme-
diates represented the dominant form of COX and COX monomer
Fig. 3. Analysis of COX assembly in SURF1-deﬁcient mouse and human ﬁbroblasts following the release of doxycycline-arrested mitochondrial protein translation. BNE/SDS PAGE
representative Western blot analysis using antibody to COX1 subunit performed in doxycycline treated (A) human control and (B) SURF1 patient ﬁbroblasts and (C) SURF1+/+ and
(D) SURF1−/−mouse ﬁbroblasts. For BNE analysis, cell membranes were isolated and solubilized by digitonin (4 g dig/g protein). COX1 assembly intermediates (AI), COX monomer
(M), COX supercomplexes (SC) are marked. Control cells without DOX (C-DOX), times t0–t96 represent time points in hours after DOX removal, when the cells were harvested. Two
independent DOX experiments for each cell line were performed to generate 2D maps showing distribution of COX1 forms along the DOX experiments at time points t0–t96 h (0 h–
96 h) in (E) human control and (F) SURF1 patient ﬁbroblasts and (G) SURF1+/+ and (H) SURF1−/− mouse ﬁbroblasts. Relative quantities of individual COX forms (assembly
intermediates, monomer, dimer, supercomplexes) were used to divide the respective COX1 signal for given time point from 1D SDS PAGE (see Fig. 4 E–H in the Data in Brief
appendix), normalized to SDHA signal. The resulting datasets from each experiment representing individual COX forms in human and mice cells were rescaled (minimum = 0,
maximum= 100) and averaged to plot in comparative 2D maps. COX assembly intermediates (AI), COX monomer (M), COX supercomplexes (SC).
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patient did not reach the steady state levels observed in cells without
DOX treatment even at t96 h.
The shift in balance between COX monomer and AI towards the AI
was also clearly observable in SURF1−/− mouse ﬁbroblasts and was
maintained throughout the time course as in SURF1 patients' cells.
However, in other aspects, mouse and human models differed. First,
the incorporation of newly synthesized COX subunits into higher SCs
was delayed in mouse ﬁbroblasts and only started to appear at t16–
24 h (Fig. 3 C, D, G, H). Also, the COX SCs represented onlyminor portion
of COX, which was just barely detectable by COX1 antibody in mouse
cells without DOX treatment both on SURF1+/+ and SURF1−/− back-
ground. The COX monomer was the dominant COX form in all mouse
cells; it increased signiﬁcantly in SURF1+/+ cells from t0 to t96 h, while
in SURF1−/− cells AI represented up to 50% of COX1 signal, gradually
accumulating at the respective time points.
The interspecies differences between mouse and human ﬁbroblasts
are clearly visualized in 2D maps of COX distribution into individual
forms (Fig. 3 E–H). In human ﬁbroblasts (Fig. 3 E, F), COX incorporation
into SCswasmuchmore prevalent than inmouse cells (Fig. 3 G, H), con-
trol human cells maintained stable proportion between COX monomer
and SCs, whereas SURF1 patient cells preferentially incorporated the as-
sembled COX into SCs rather than into COXmonomer. In SURF1+/+ andSURF1−/− mouse cells (Fig. 3 G, H), COX SCs amount was negligible
when compared to COX monomer. DOX experiment thus clearly
showed COX assembly defect due to SURF1 gene mutation/knock out.
SURF1 patients' cells accumulated more COX assembly intermediates
and most of assembled COX incorporated into SCs, whereas SURF1−/−
mouse cells accumulated less COX AI and were characterized by more
stable COX monomer compared to SURF1 patient.
3.5. Pulse-chase labeling of mitochondrially encoded COX subunits
As a follow up on the doxycycline experiments aimed at comparison
of control and SURF1 defective human and mouse ﬁbroblasts, we ana-
lyzed the assembly kinetics of COX directly by pulse-chase 35S labeling
of mitochondrial translation products. Fibroblast cell lines pretreated
with chloramphenicol (16 h/overnight) were washed and pulsed with
35S labeled Met-Cys in the presence of cycloheximide (CHX). Cells
were then chased with cold Met-Cys without CHX at time points 0.5 h,
6 h, 16 h, 24 h to follow the time course of newly synthesized COX1,
COX2, and COX3 subunits incorporation into assembly intermediates,
monomer and SCs of COX. Isolated cell membranes were analyzed by
2D BNE/SDS PAGE after solubilization with digitonin (4 g/g protein).
In control human ﬁbroblasts we observed themajor portion of COX1
incorporated in assembly intermediates, whereas a small part was
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0.5 h (Fig. 4 A; Fig. 5 A). COX2 and COX3 subunits followed the same
pattern but themigration distance and thus the identity of their respec-
tive assembly intermediates differed fromCOX1 (Fig. 4 A). At chase time
16 h, COX AI signal considerably decreased, accompanied by the
increase of remaining forms, i.e. COX monomer, COX dimer and COX
SCs. This pattern was consistent for signals from all three mtDNA
encoded COX subunits. At the 24 h chase, COX monomer became the
dominant form, and the COX1 assembly intermediates almost disap-
peared. In the case of SURF1patient cells (Fig. 4 B; Fig. 5 B), COX1 assem-
bly intermediates clearly dominated at chase 0.5 h. Small portion of COX
monomer and SCs were also present, but they are only distinguishable
from the signals of COX2 and COX3 subunits (Fig. 4 B). At chase 16 h,
COX1 assembly intermediates still represented the dominant COX
form, with small portion of COX1 shifting to the monomer as well as
into COX SCs. At the end of the chase periods at t24 h, the signals of
COX subunitsweakened in patient cells, but the amount of COX1 assem-
bly intermediates still prevailed over the fully assembled COX forms.
When we analyzed the COX assembly kinetics in SURF1+/+ mouse
ﬁbroblasts (Fig. 4 C; Fig. 5 C), we observed high amount of COX1 assem-
bly intermediates, but also considerable signal of fully assembled new
COX monomer and beginning of SCs formation at chase time 0.5 h. At
longer chase periods COX1 assembly intermediates almost disappeared.
We were able to detect COX monomer together with COX dimer, and
COX-containing SCs, similar to the observation in DOX experiment
using COX1 antibody from time point t24 h onwards. In SURF1−/−
mouse ﬁbroblasts at time points 0.5 h and 6 h, the formation of COX1Fig. 4. Pulse-chase metabolic labeling of mitochondrially synthesized proteins in SURF1-deﬁcie
D) SURF1+/+ and SURF1−/− mouse ﬁbroblasts. Mitochondrial translation products of mous
presence of cycloheximide. After indicated time of chase (0.5 h, 6 h, 16 h, 24 h) with cold m
protein) and analyzed by BNE/SDS PAGE. Radioactivity was detected in stained dried gels. O
coded COX subunits COX1, COX2, COX3 are highlighted in frames. COX assembly intermediateAI was prevailing over the signal of monomer (Fig. 4 D; Fig. 5 D), similar
to human SURF1 patient cells. However, at later time points COX1 as-
sembly intermediates rapidly disappeared, whereas newly synthesized
COX monomer appeared stable, and only its content was clearly de-
creased when compared to SURF1+/+ mouse cells. As in SURF1+/+
mouse cells, large I–III2–IVn SCs were clearly detected.
In both SURF1−/− and SURF1 patientﬁbroblasts the amount of newly
synthesized COX1 subunit during the pulse (t0.5 h) reaches approxi-
mately 70–80% of respective control levels. While an increase in COX1
translation could result in the apparent increase in the amount of COX
monomer in SURF1−/− cells, this does not seem to be the case in our
model.
Taken together, also when followed by pulse-chase, the COX assem-
bly kinetics in mouse SURF1+/+ and SURF1−/− ﬁbroblasts showed sig-
niﬁcant differences from the respective human cells, particularly
regarding COX assembly intermediates depletion/accumulation and
stability of COX monomer. As can be seen from 2D maps in Fig. 5 A–D,
control human cells became depleted of COX AI at later time point
(chase t24 h) than SURF1+/+mouse cells (chase t16 h), which indicates
possible slower COX1 biogenesis in humans. Also, SURF1−/− mouse
ﬁbroblasts coped better with SURF1 protein absence; they accumulated
less COX AI and were able to synthesize more stable COX monomer
when compared to SURF1 patient cells, where the SURF1 seems to be
crucial for effective COX1 biogenesis and its incorporation to COX
monomer.
The assembly kinetics of mtDNA subunits for other OXPHOS com-
plexes, e.g. cytochrome b of cIII or ATP6 and 8 of cV, was comparablent mouse and human ﬁbroblasts. (A, B) Human control and SURF1 patient ﬁbroblasts, (C,
e and human ﬁbroblasts were labeled with [35S] methionine + cysteine for 2 h in the
ethionine and cysteine, cell membranes were isolated, solubilized by digitonin (4 g/g
n the right side of each gel, individual mtDNA coded subunits are marked and mtDNA
s (AI), COX monomer (M) are marked by dotted lines; COX SCs (SC).
Fig. 5. 2D maps of pulse-chase metabolic labeling of mitochondrially synthesized COX1 subunit. (A) Human control and (B) SURF1 patient ﬁbroblasts, (C) SURF1+/+ and (D) SURF1−/−
mouse ﬁbroblasts. 2D maps show biogenesis of COX1 subunit along the pulse-chase experiment at chase times t0.5, t6, t16 and t24 h (0.5 h–24 h). Relative quantities of individual
COX forms (assembly intermediates, monomer, supercomplexes) were used to divide the respective COX1 signal for given time chase from 1D SDS PAGE, normalized to overall
radioactive signal in each time chase. The resulting datasets from each experiment representing individual COX forms in human and mouse cells were rescaled (minimum = 0,
maximum= 100) and plotted in comparative 2D maps. COX assembly intermediates (AI), COX monomer (M), COX supercomplexes (SC).
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mouse cells (Fig. 4 A–D), as can be expected for isolated COX defect.
4. Discussion
In the present study we analyzed the COX biogenesis from assembly
intermediates (AI) to supercomplexes (SC) in tissues and ﬁbroblasts
from SURF1−/− mouse and SURF1 patient ﬁbroblasts to address the
observed tissue and interspecies differences in phenotype severity. To
characterize changes at steady state conditions as well as the dynamics
of COX de novo synthesis, we combined enzyme activity measurements,
2D PAGE/immunodetection on doxycycline arrested cells and 35S-
labeling of mtDNA encoded proteins.
Numerous studies indicate that SURF1 protein (SURF1) promotes
early stages of COX biogenesis, from COX1 translation regulation to its
association with other COX subunits into COX AI [20,42,58,62]. Despite
the absence of SURF1, 10–30% of control amount of active COX is assem-
bled in SURF1 patients' ﬁbroblasts [44]. Thus, while improving its efﬁca-
cy, SURF1 is not absolutely essential in the COX assembly process [52].
Decreased levels of COX holoenzyme and reduction of COX activity
were found to be accompanied by decreased levels of COX subunits
[44,69] and accumulation of speciﬁc COX AIs. In SURF1 patients, COX
subcomplexes were detected in primary ﬁbroblasts, skeletal muscle
and heart, while their amount was very low in liver and brain [59,60,
62]. Likewise, we have also observed tissue variance in COX assemblyprocess in SURF1−/−mouse tissues onWestern blots, wherewe detected
markedly variable amount of accumulated COX1-containing sub-
complexes (Fig. 1 A–D). However, the severity of COX assembly defect
in tissues from SURF1−/− mouse was not as pronounced as in
SURF1−/− mouse ﬁbroblasts possibly because the assembly defect
better manifests in proliferating cell cultures than in largely post-mitotic
tissues studied (Fig. 1 E, F).
4.1. COX subassemblies and formation of monomer
Observed COX1-containing subcomplexes can either be COX degra-
dation products or more likely represent true AIs, as they are predomi-
nantly labeled already at the shortest chase times (t0.5 h, Fig. 4 A–D).
Furthermore, AIs labeling gradually decreased during the chase, in con-
trast to the increase in the COXmonomer signal. However, AI dynamics
differed between human and murine models of SURF1 deﬁciency. In
SURF1 patient ﬁbroblasts, COX1-subassemblies persisted throughout
the chase without the progression into COX monomer. Contrariwise,
SURF1−/− mouse ﬁbroblasts had higher content of COX monomer
from the beginning and its levels remained stable from t6 h onwards,
while COX1 AIs gradually disappeared between t16–24 h, arguing for
considerably faster turnover of COX1 AIs in mouse cells.
This is in line with our doxycycline (DOX) treatment experiments.
COX1-subassemblies detected in lesser amount also in both types
of control cells most likely reﬂect signiﬁcant limiting step of COX
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of catalytic components of the enzyme (hemes, CuB). Fittingly, in
bacteria [13,23] and yeast the SURF1 homologs were linked with
heme a incorporation into COX1. Shy1 — yeast homolog of SURF1 —
forms early assembly intermediatewith COX1 [39]. In this intermediate,
both heme a cofactor sites are most likely formed in a stepwise process
— heme a in a transition to the Shy1-containing complex and heme a3
within Shy1 complex. CuB site was also suggested to be formed at
this stage, since Shy1 was found to transiently interact with CuB
metallochaperone COX11. Thus, formation of heterobimetallic CuB-
heme a3 site should occur in the Shy1 complex [27]. In addition, Shy1
was found also in association with COX15, heme a synthase, most likely
cooperating on heme a transfer and insertion into early COX1 assembly
intermediates [7]. While SURF1 can likely function analogously in the
mammalian cells, this has yet to be experimentally proved. As in case
of mammalian SURF1, Shy1 seems not to be absolutely required for
COX1 maturation steps, because yeast strains lacking Shy1 have still
residual fully assembled and active COX.
Interestingly, the assembly process seems to proceed faster inmouse
than in human ﬁbroblasts. Thus, at chase time point 16 h, all COX1 in
mouse cells was assembled in holoenzyme while in human ﬁbroblasts
a signiﬁcant portion of the subunit was still present in assembly inter-
mediates. This could be due to a higher reservoir of COX1 AIs in control
human cells and, along with faster decomposition of stalled AIs, may
partially explain the milder phenotype of SURF1 absence in mouse.
Faster assembly and rapid recycling of unincorporated subunits in
mouse system would result in more frequent assembly “attempts”
producing higher steady state COX content than in human patient cells.
On the contrary, translational activation of COX1 speciﬁcally in
mouse cells may yield analogous outcome. In this respect, the pheno-
type of yeast Shy1 mutant was partially restored by the suppressor
MSS51 through increased translation of COX1 [8]. Mss51p is primarily
speciﬁc translation factor for COX1mRNA, that acts on the 5′ untranslat-
ed region (UTR) of COX1 mRNA to promote translation initiation [27].
However, mammalian mitochondrial mRNAs do not have signiﬁcant
5′ UTRs [40] and this may be the reason why functional homolog of
translation activator Mss51p has not been found yet. On the other
hand, human homolog (LRPPRC) of the yeast translational activator
Pet309 has been reported and, in addition, translational activator of
COX1 TACO1 is necessary for efﬁcient translation of COX1 [64]. These
proteins, or other yet unidentiﬁed factor(s), may effectively act as
species-speciﬁc suppressors of COX defects in SURF1−/− mouse cells.
Larger pool of translated COX1 accessible for ﬁnishing of COX1 matura-
tionwithout SURF1may then lead to synthesis of higher amount of COX
and thus be the cause of themilder COXdefect in SURF1−/−mouse cells.
However, our data do not support such possibility. As already men-
tioned the decrease in the amount of newly synthesized COX1 subunit
was approximately equal in both mouse and human ﬁbroblasts with
SURF1 defect without any indication of compensatory upregulation in
mouse cells.
Impaired COXbiogenesis due to SURF1 deﬁciency is characterized by
accumulation of the S2 intermediate containing COX1–COX4–COX5a
subunits [20,42]. S2 represents an important rate limiting step and can
usually be detected even in control cells/tissues. Recently, MITRAC com-
plexes (mitochondrial translation regulation assembly intermediates of
COX)were described as part of COX biogenesis pathway [38]. Their sug-
gested function lies in regulation of COX1 translation by coordinating
the interaction of COX1 with speciﬁc assembly proteins before entering
the further steps of COX assembly. This regulatory cycle should be actu-
ally considered as an alternative mechanism of COX1 biogenesis in
mammals to that in yeast. SURF1 was also found to be part of MITRAC
complexes together with hCOA3 (MITRAC12) [15] and other COX as-
sembly proteins (COX15, COX16, C12orf62). However, it is possible
that the S2 subassemblies merely co-migrate with MITRAC complexes
on native gels. The presence of several types of complexes and/or their
dynamics in recruitment and release of various assembly factors hasbeen reﬂected in changes of migration patterns of COX1-containing as-
semblies in 2D gels.We propose that absence of SURF1 does not exclude
formation of MITRAC complexes and their accumulation with S2 subas-
semblies. Indeed, we consistently detect complexes that may represent
such associations in COX defective cells/tissues characterized by im-
paired efﬁciency of COX1 biogenesis and its delayed interaction with
other COX subunits.
4.2. COX incorporation into supercomplexes
COX holoenzyme is known to interact with other RC complexes and
form supercomplexes (SCs) [21,25,41,54]. However, in allmouse tissues
examined in this study, COX monomer represented the dominant COX
form. We also detected the presence of COX dimer and III2–IV SC and
these forms were decreased or even disappeared in SURF1−/−mouse.
The signal of large I–III2–IVn SCs was quite weak in SURF1+/+ mouse
heart and muscle despite the fact that these SCs are usually observed
in digitonin solubilizates [53,67]. Interestingly, several recent studies
reported the absence of COX SCs (III2–IV and I–III2–IVn) in liver and
ﬁbroblasts from C57Bl/6 J mouse strain, which served also as the paren-
tal strain for formation of SURF1−/−mouse [16,29]. This was associated
with the presence of short isoform of COX7a2l (SCAFI) subunit in this
strain, which may preclude SC formation.
The relative absence of SCs in mouse samples contrasted with our
observations in human ﬁbroblasts, where we found strong signal of
I–III2–IVn SCs. Therefore, we usedDOX to analyze species-speciﬁc differ-
ences of COX ability to interact into SCs in control and SURF1 deﬁcient
human/mouse ﬁbroblasts. In control human ﬁbroblasts the COX1 signal
increased equally in all detectable COX forms (AI, M, SCs), indicating a
stable balance in distribution of COX forms. Due to decreased amount/
stability of COX monomer, the SURF1-deﬁcient patient ﬁbroblasts pref-
erably incorporated COX into I–III2–IVn SCs for its stabilization [28,30].
On the other hand, in mouse ﬁbroblasts assembly kinetics of COX
proceededmostly just to the level of COXmonomer. COX SCs formation
was delayed, and although their content even exceeded the levels in un-
treated cells, these higher forms of COX represented just a small portion
of the total COX quantity. This is themost important difference between
SURF1−/−mouse and SURF1 patient ﬁbroblasts we uncovered. The pref-
erence towards SCs incorporation is not unique to SURF1 human pa-
tients. Recent study on cybrid clones carrying the heteroplasmic
cytochrome bm.15579 A N G mutation demonstrated that its deleteri-
ous effects were attenuated when cIII was assembled into I–III2–IVn
SCs [14].
There is only limited amount of information available about COX as-
sembly kinetics after DOX mediated inhibition. The most comprehen-
sive study was performed in control cybrids (143B cells) and DOX
caused strong decrease of overall COX signal and disappearance of
COX SCs. Gradual incorporation of the COX into SCs was observed at
6 h after DOX removal and COX1 appeared in SCs even later [41]. In
our human ﬁbroblasts, about 30% of various COX assemblies remained
after DOX treatment and also COX SCswere partially preserved. Similar-
ly, mouse ﬁbroblasts started to synthesize COX SCs a few hours after
DOX removal, but in the end favored COXmonomer as amain function-
al COX form. Control human and mouse ﬁbroblasts resembled
cybrid cells [41,45] as the amount of COX totally recovered 96 h after
DOX treatment. Milder COX defect in SURF1−/−mouse ﬁbroblasts also
allowed the cells to reach the steady state after 96 h period, but SURF1
patient cells were delayed in COX recovery, again pointing towards
slower and more affected COX biogenesis.
In conclusion, our present study shows that COX in tissues or cells
from the SURF1+/+ and SURF1−/− mice exerts lower preference to be
incorporated into SCs. On the other hand, I–III2–IVn SCs represented
an important functional forms of COX in human cells, and even more
so in SURF1 patient ﬁbroblasts. Another reason why the defect caused
by SURF1 absence in mice is less dramatic when compared to SURF1 pa-
tients is that COX monomer seems to be more stable in SURF1−/−mice
714 N. Kovářová et al. / Biochimica et Biophysica Acta 1862 (2016) 705–715and at the same time the turnover of accumulated COX assembly inter-
mediates is faster.
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